Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2017, Pages 652-662

  Hong, Ying ^a   Passos, Vanessa Q ^a   Huang, Pai Hsi ^a   Lau, Yvonne Y ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

anaplastic lymphoma kinase; ceritinib; NSCLC; population pharmacokinetic analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANAPLASTIC LYMPHOMA KINASE; BILIRUBIN; CERITINIB; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; CANCER GENETICS; CANCER PATIENT; CLEARANCE AT STEADY-STATE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG ELIMINATION; DRUG EXPOSURE; ENZYME INHIBITION; ETHNICITY; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MILD HEPATIC IMPAIRMENT; NONLINEAR SYSTEM; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TIME; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; MUTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; MALE; MODELS, BIOLOGICAL; MUTATION; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 85017537997     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.849     Document Type: Article

References (16)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
2. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–673.
3. Zykadia® [USPI]. http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf. East Hanover, NJ: Novartis Pharmaceuticals Corporation; revised July 2015.
4. Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873.
5. Clinical pharmacology and biopharmaceutics review(s) of ceritinib. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. Accessed June 8, 2015.
6. European Medicines Agency. Zykadia® (ceritinib) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003819/WC500187504.pdf. Accessed June 8, 2015.
7. Zykadia®(ceritinib) [European public assessment report]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003819/WC500187506.pdf. Accessed June 8, 2015.
8. Kim D, Mehra R, Tan DSW, et al. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Int J Radiat Oncol Biol Phys. 2014;9(5):S33–S34.
9. Nishio M, Murakami H, Horiike A, et al. Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors. J Thorac Oncol. 2015;10(7):1058–1066.
10. Felip E, Orlov S, Park K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8060.
11. Heudi O, Vogel D, Lau YY, Picard F, Kretz O. Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies. Anal Bioanal Chem. 2014;406(28):7389–7396.
12. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982:305.
13. Wählby U1, Thomson AH, Milligan PA, Karlsson MO. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol. 2004;58(4):367–377.
14. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151.
15. ClinicalTrials.gov. U.S. National Institutes of Health. Identifier NCT01950481. Effect of Hepatic Impairment on LDK378 Pharmacokinetics. https://clinicaltrials.gov/ct2/show/NCT01950481?term=ceritinib±hepatic±impairment&rank=1. Accessed June 8, 2015.
16. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15(3):355–370.